Avidity Biosciences is pioneering a new class of precision medicines – antibody-siRNA conjugates (ASC™) – to deliver nucleic acid therapeutics against genetic drivers of disease.  Our ASCs have drug-like properties similar to antibodies and antibody-drug conjugates.  Importantly, their unique siRNA-based “payloads” permit selective targeting of disease-associated mRNAs against virtually any target of interest.

Biotechnology

Education

Avidity

Sarah Boyce

Anneke Raney

Sarah Hudson, PhD, PMP®

Eric Mosbrooker

Marc Morris, MD JD

Teresa Brandt, PhD

Mike Flanagan

Mike MacLean

Joseph Johnston

Husam Younis

Elizabeth J Ackermann PhD

Michael MacLean

Steve Hughes

W. Michael Flanagan

John W. Wallen III

Teresa McCarthy

Arthur A. Levin

The Clinical Operations Team at Avidity Biosciences manages the planning, execution, and oversight of clinical trials for ASC™ therapies. They ensure that clinical studies are conducted efficiently, ethically, and within regulatory guidelines, coordinating between various departments to collect, manage, and analyze clinical data. The team is also responsible for optimizing health economics and outcomes research to demonstrate the therapeutic value of ASC™ treatments.

Clinical Operations Team

Scientific Research Team

Leadership Team

Clinical Operations Team

About

Team members

Other teams at Avidity

Scientific Research Team

Leadership Team